
    
      This study is a multicenter, prospective phase II-study compares efficacy of allogeneic SCT
      for patients with myelofibrosis who have a suitable stem cell donor after a 3 months
      Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will
      continue to receive Ruxolitinib.

      In this study will further assess and compare the safety and efficacy of study treatments/
      induction therapy in both study arms on spleen reduction, improvement of constitutional
      symptoms, QOL, toxicity, fibrosis regression, development of GvHD as well as chimerism,
      engraftment, relapse incidence, disease related mortality, outcome and overall survival.
    
  